Sergey Sikora

Dr. Sikora has 8 years of management and 12 years of biomedical research experience. His area of expertise is Diagnostics and Therapeutics in Cardiology. Prior  to Stemedica he worked at GenWay between 2006 and 2013 as Senior Vice President, in charge of Custom, Catalog, and FirstMark Cardiology Diagnostics Divisions. Within a short period of time, he was able to establish business development related to GenWay’s proprietary IgY microbead technology, Seppro® system. He also established and led FirstMark Diagnostic Division at GenWay. He has taken the lead in forming partnerships, agreements and sales for GenWay’s custom services business, and he plays a key role in the development of the Company’s diagnostic FirstMark business. He is also Chair of Scientific Advisory Board for the FirstMark. The Board is comprised of top Key Opinion Leaders in US Cardiology. In 2008 Dr. Sikora successfully divested two largest divisions of GenWay to Sigma-Aldrich.

Prior to joining GenWay, Dr. Sikora was a founder and Vice President of Business Development in MC-Fibers. During his tenure in MC-Fibers, he successfully established a customer base and developed the business strategy for the company.. During his work at the Burnham Institute, Dr. Sikora developed a novel bioinformatics/experimental biology streamlining method for rapid experimental conformation of computational predictions, analyzed the SARS genome which resulted in a U.S. patent and published a number of research articles.

Dr. Sikora obtained his MBA degree from the Rady School of Management at the University of California, San Diego and his Ph.D. degree from UCLA. Dr. Sikora received his undergraduate degree in Biochemistry from UCLA with cum laude.